Unstable Angina Clinical Presentation
- Author: Walter A Tan, MD, MS; Chief Editor: Eric H Yang, MD more...
History
Patients with unstable angina represent a heterogeneous population. Therefore, the clinician must obtain a focused history of the patient's symptoms and coronary risk factors and immediately review the ECG to develop an early risk stratification. (See Prognosis.)
Initially obtain a history to determine whether any evidence of angina is present, and then aim to identify whether it is stable or unstable.
Physical Examination
The physical examination is usually not as sensitive or specific for unstable angina as history or diagnostic tests. An unremarkable physical examination is not uncommon. Perform a quick assessment of patients' vital signs, and perform a cardiac examination. Specific diagnoses that must be explicitly considered are the following:
- Aortic dissection
- Leaking or ruptured thoracic aneurysm
- Pericarditis with tamponade
- Pulmonary embolism
- Pneumothorax
Unstable angina differs from stable angina in that the discomfort is usually more intense and easily provoked, and ST-segment depression or elevation on ECG may occur. Otherwise, the manifestations of unstable angina are similar to those of other conditions of myocardial ischemia, such as chronic stable angina and myocardial infarction.
Angina can take many forms, and inquiry should be directed at eliciting not only chest pain but also any discomfort and its frequency, location, radiation pattern, and precipitating and alleviating factors. Ischemic pain can manifest as heaviness, tightness, aching, fullness, or burning of the chest, epigastrium, and/or arm or forearm (usually the left). These sensations less typically involve the lower jaw, neck, or shoulder. Important associated symptoms may be dyspnea, generalized fatigue, diaphoresis, nausea and vomiting, flulike symptoms, and, less commonly, lightheadedness or abdominal pain.
Elderly and female patients are more likely to present with atypical signs and symptoms.
Increased autonomic activity may manifest as diaphoresis or tachycardia, and bradycardia may result from vagal stimulation from inferior wall myocardial ischemia.
A large area of myocardial jeopardy may manifest as signs of transient myocardial dysfunction and typically signifies a higher-risk situation. Signs include the following:
- Systolic blood pressure less than 100 mm Hg or overt hypotension
- Elevated jugular venous pressure
- Dyskinetic apex
- Reverse splitting of the second heart sound
- Presence of a third or fourth heart sound
- New or worsening apical systolic murmur due to papillary muscle dysfunction
- Rales or crackles
Patients with acute coronary syndrome may present with a chief symptom of pain or discomfort in the chest or left arm, particularly if it reproduces previously documented angina.
Findings indicative of peripheral arterial occlusive disease or prior stroke increase the likelihood of associated coronary artery disease and are as follows:
- Carotid bruit
- Supraclavicular or femoral bruits
- Diminished peripheral pulses or blood pressure
Any sign of congestive heart failure, including isolated tachycardia, particularly in physiologically vulnerable populations (eg, very elderly patients), should trigger expeditious workup, treatment, or consultation with a cardiologist. Such patients can deteriorate rapidly.
The number and diversity of clinical conditions that cause the transient myocardial ischemia of unstable angina along with its varying intensity and frequency of pain have made classification within this disorder difficult.
Braunwald Classification
The Braunwald classification is conceptually useful because it factors in the clinical presentation (new or progressive vs rest angina), context (primary, secondary, or post–myocardial infarction), and intensity of antianginal therapy.
Table 4. Braunwald Classification of Unstable Angina (Open Table in a new window)
| Characteristic | Class/Category | Details |
| Severity | I | Symptoms with exertion |
| II | Subacute symptoms at rest (2-30 d prior) | |
| III | Acute symptoms at rest (within prior 48 h) | |
| Clinical precipitating factor | A | Secondary |
| B | Primary | |
| C | Postinfarction | |
| Therapy during symptoms | 1 | No treatment |
| 2 | Usual angina therapy | |
| 3 | Maximal therapy |
Patients in class I have new or accelerated exertional angina, whereas those in class II have subacute (>48 h since last pain) or class III acute (< 48 h since last pain) rest angina. The clinical circumstances associated with unstable angina are categorized as (A) secondary (anemia, fever, hypoxia), (B) primary, or (C) postinfarction (< 2 wk after infarction). Intensity of antianginal therapy is subclassified as (1) no treatment, (2) usual oral therapy, and (3) intense therapy, such as intravenous nitroglycerin.
Canadian Cardiovascular Society Grading System
The Canadian Cardiovascular Society Grading System for effort-related angina is widely used since it is a simple and practical classification that is often used to describe symptom severity. The grading system is as follows:
- Grade I - Angina with strenuous, rapid, or prolonged exertion (Ordinary physical activity such as climbing stairs does not provoke angina.)
- Grade II - Slight limitation of ordinary activity (Angina occurs with postprandial, uphill, or rapid walking; when walking more than 2 blocks of level ground or climbing more than 1 flight of stairs; during emotional stress; or in the early hours after awakening.)
- Grade III - Marked limitation of ordinary activity (Angina occurs with walking 1-2 blocks or climbing a flight of stairs at a normal pace.)
- Grade IV - Inability to carry on any physical activity without discomfort (Rest pain occurs.)
Acute Coronary Syndrome Risk Assessment
Estimation of the likelihood of acute coronary syndrome is a complex, multivariable problem that cannot be fully specified in the below list. The following is meant to illustrate major relationships rather than to offer rigid algorithms.
High likelihood of acute coronary syndrome includes any of the following features:
- History of prior myocardial infarction, sudden death, or other known history of coronary artery disease
- Chest or left arm pain consistent with prior documented angina
- Transient hemodynamic or electrocardiographic changes during pain
- ST-segment elevation or depression 1 mm or more
- Marked symmetrical T-wave inversion in multiple precordial leads
Intermediate likelihood of acute coronary syndrome includes the absence of high-likelihood features but the presence of 1 of these risk characteristics:
- Age older than 70 years
- Male sex
- Diabetes mellitus
- Extracardiac vascular disease (peripheral, brachiocephalic, or renal artery atherosclerosis)
- ST depression 0.05-1 mm
- T-wave inversion 1 mm or greater in leads with dominant R waves
Low likelihood of acute coronary syndrome includes the absence of high- or intermediate-likelihood features and the presence of any of the following:
- Chest pain classified as probably not angina
- Chest discomfort reproduced by palpation
- T-wave flattening or inversion of less than 1 mm in leads with dominant R waves
- Normal electrocardiographic findings
Thrombolysis in Myocardial Infarction Risk Score
The TIMI Risk Score for unstable angina/NSTEMI is currently the best-validated prognostic instrument that is simple enough to use in an emergency department setting. The gradient of myocardial infarction, severe recurrent ischemia, or death is somewhat proportionate to the TIMI Risk Score (see the graphs below), although an adverse prognosis appears to be mitigated by the use of newer antithrombotic strategies.
Thrombolysis in Myocardial Infarction (TIMI) Risk Score correlates with major adverse outcome and the effect of therapy with low molecular weight heparin. The inflection point for myocardial infarction or death starts at a TIMI Risk Score of 3. Therefore, patients with a score of 3-7 should be considered for use of intravenous glycoprotein IIb/IIIa agents, heparin (low molecular weight or unfractionated), and early cardiac catheterization (see Treatment and Management).
The presence of any of the following variables constitutes 1 point, with the sum constituting the patient risk score on a scale of 0-7:
- Aged 65 years or older
- Use of aspirin in the last 7 days
- Known coronary stenosis of 50% or greater
- Elevated serum cardiac markers
- At least 3 risk factors for coronary artery disease (including diabetes mellitus, active smoker, family history of coronary artery disease, hypertension, hypercholesterolemia)
- Severe anginal symptoms (2 or more anginal events in the last 24 h)
- ST deviation on ECG
Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. Jan 20 2011;364(3):226-35. [Medline].
Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. Aug 12 2008;52(7):523-7. [Medline].
Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. Nov 15 1999;84(10):1145-50. [Medline].
GRACE, Global Registry of Acute Coronary Events. Available at http://www.outcomes-umassmed.org/grace/. Accessed September 16, 2010.
Lupón J, Valle V, Marrugat J, Elosua R, Serés L, Pavesi M, et al. Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. Dec 1999;34(7):1947-53. [Medline].
Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet. Mar 26 2011;377(9771):1077-84. [Medline].
Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. Nov 2004;27(11):607-10. [Medline].
de Zwaan C, Bar FW, Wellens HJ. Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction. Am Heart J. Apr 1982;;103(4 Pt 2):730-6. [Medline].
Nisbet BC, Zlupko G. Repeat Wellens' syndrome: case report of critical proximal left anterior descending artery restenosis. J Emerg Med. Sep 2010;39(3):305-8. [Medline].
Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. Jun 13 2006;113(23):2733-43. [Medline].
Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. Sep 2 2008;118(10):1011-20. [Medline]. [Full Text].
[Guideline] Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Mar 28 2011;[Medline].
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494-502. [Medline].
Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. Oct 7 2003;108(14):1682-7. [Medline].
Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. Nov 24 2011;365(21):1980-9. [Medline].
Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. Jul 16 1992;327(3):141-5. [Medline].
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. Apr 4 2001;285(13):1711-8. [Medline].
Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. Dec 15 2009;54(25):2358-62. [Medline].
Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. Dec 1995;26(7):1643-50. [Medline].
Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. Jun 18 1998;338(25):1785-92. [Medline].
Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].
[Guideline] Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].
[Guideline] American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. Jan 2010;33 Suppl 1:S11-61. [Medline]. [Full Text].
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329-39. [Medline].
- Table 1. Patient Characteristics, GUARANTEE Versus CRUSADE
- Table 2. Demographic Characteristics of Patients in the International OASIS-2 Registry
- Table 3. Thirty-Day Clinical Outcome in Patients With Acute Coronary Syndromes in Clinical Trials
- Table 4. Braunwald Classification of Unstable Angina
- Table 5. AHA/ACC Recommendations for a Preferred Invasive Strategy
| GUARANTEE, 1995-96 | CRUSADE, 2001-06 | |
| Mean age | 62 years | 69 years |
| Patients older than 65 years | 44% | |
| Female | 39% | 40% |
| Hypertension | 60% | 73% |
| Diabetes mellitus | 26% | 33% |
| Current smoker | 25% | |
| Hypercholesterolemia | 43% | 50% |
| Previous stroke | 9% | |
| Previous myocardial infarction | 36% | 30% |
| Previous angina | 66% | |
| Congestive heart failure | 14% | 18% |
| Previous coronary intervention | 23% | 21% |
| Previous coronary bypass surgery | 25% | 19% |
| Characteristics | Australia | Brazil | Canada | Hungary | Poland | United States | |
| General | Number of patients | 1899 | 1478 | 1626 | 931 | 1135 | 918 |
| Mean age (y) | 65 | 62 | 66 | 65 | 63 | 66 | |
| Women (%) | 37 | 42 | 37 | 45 | 40 | 37 | |
| Clinical | NQMI presentation (%) | 7 | 7 | 14 | 22 | 17 | 16 |
| Abnormal electrocardiogram (ECG)( %) | 74 | 91 | 82 | 95 | 97 | 87 | |
| Select treatments | Beta-blocker (%) | 67 | 53 | 73 | 67 | 59 | 57 |
| Calcium blocker (%) | 59 | 51 | 53 | 52 | 43 | 59 | |
| Invasive procedures (index hospitalization) | Cardiac catheterization (%) | 24 | 69 | 43 | 20 | 7 | 58 |
| Percutaneous coronary intervention (PCI) (%) | 7 | 19 | 16 | 5 | 0.4 | 24 | |
| Coronary artery bypass graft (CABG) (%) | 4 | 20 | 10 | 7 | 0.4 | 17 | |
| Study | Year | Number of Patients | Death (%) | Myocardial infarction (%) | Major Bleed (%) |
| TIMI-3* | 1994 | 1,473 | 2.5 | 9.0 | 0.3 |
| GUSTO-IIb † | 1997 | 8,011 | 3.8 | 6.0 | 1.0 |
| ESSENCE ‡ | 1998 | 3,171 | 3.3 | 4.5 | 1.1 |
| PARAGON-A § | 1998 | 2,282 | 3.2 | 10.3 | 4.0 |
| PRISM || | 1998 | 3,232 | 3.0 | 4.2 | 0.4 |
| PRISM-PLUS ¶ | 1998 | 1,915 | 4.4 | 8.1 | 1.1 |
| PURSUIT# | 1998 | 10,948 | 3.6 | 12.9 | 2.1 |
| TIMI-11B** | 1999 | 3,910 | 3.9 | 6.0 | 1.3 |
| PARAGON-B †† | 2000 | 5,225 | 3.1 | 9.3 | 1.1 |
| Pooled | 40,167 | 3.5 | 8.5 | 1.5 | |
| * TIMI-3: Thrombolysis in Myocardial Infarction Clinical Trial 3 † GUSTO-IIb: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. ‡ ESSENCE: Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events. § PARAGON-A: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network. || PRISM: Platelet Receptor Inhibition in Ischemic Syndrome Management. ¶ PRISM-PLUS: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms. # PURSUIT: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. ** TIMI-11B: Thrombolysis in Myocardial Infarction Clinical Trial 11B. †† PARAGON-B: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network | |||||
| Characteristic | Class/Category | Details |
| Severity | I | Symptoms with exertion |
| II | Subacute symptoms at rest (2-30 d prior) | |
| III | Acute symptoms at rest (within prior 48 h) | |
| Clinical precipitating factor | A | Secondary |
| B | Primary | |
| C | Postinfarction | |
| Therapy during symptoms | 1 | No treatment |
| 2 | Usual angina therapy | |
| 3 | Maximal therapy |
| Preferred Strategy | Patient Characteristics |
| Invasive | Recurrent angina/ischemia at rest or with low-level activities despite intensive medical therapy |
| Elevated cardiac biomarkers (TnT or TnI) | |
| New or presumably new ST-segment depression | |
| Signs or symptoms of heart failure or new or worsening mitral regurgitation | |
| High-risk findings on noninvasive stress testing | |
| High-risk score (eg, TIMI, GRACE) | |
| Reduced LV systolic function (LVEF less than 40%) | |
| Hemodynamic instability | |
| Sustained ventricular tachycardia | |
| PCI within 6 months | |
| Previous CABG | |
| Conservative | Low-risk score (eg, TIMI, GRACE) |
| Patient or physician preference in the absence of high-risk features |

